Even when their tumors are shrinking in response to therapy, some non-small cell lung cancer patients have a scattering of cancer cells that are undeterred by the drug, causing the tumor to resume its growth, scientists report. The findings suggest that identifying such patients and treating them with a combination of drugs from the very start of therapy can produce longer remissions.